Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.
暂无分享,去创建一个
F. Garrido | F. Ruiz-Cabello | E. Jäger | R. Méndez | A. Knuth | A. Serrano | I. Maleno | R. Mendez | Federico Garrido
[1] F. Garrido,et al. Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.
[2] F. Garrido,et al. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. , 2000, Human immunology.
[3] N. Mehra,et al. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. , 2000, Human immunology.
[4] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[5] S. Steinberg,et al. Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.
[6] P. Hersey,et al. Impediments to successful immunotherapy. , 1999, Pharmacology & therapeutics.
[7] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[8] F. Brasseur,et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.
[9] D. Hicklin,et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. , 1998, The Journal of clinical investigation.
[10] J. Zeuthen,et al. In vivo and in vitro generation of a new altered HLA phenotype in melanoma‐tumour‐cell variants expressing a single HLA‐class‐I allele , 1998, International journal of cancer.
[11] F. Oesch,et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.
[12] P. Coulie,et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.
[13] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[14] I. Macdonald,et al. Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. , 1997, Invasion & metastasis.
[15] K. Pantel,et al. Disseminierte Tumorzellen: Diagnostik, prognostische Relevanz, Phänotypisierung und therapeutische Strategien , 1997, Der Chirurg.
[16] Yao-Tseng Chen,et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[17] F. Oesch,et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.
[18] F. Garrido,et al. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both α- and γ-interferon , 1996 .
[19] F. Real,et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. , 1996, Tissue antigens.
[20] F. Jotereau,et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.
[21] J. Karbach,et al. Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens , 1996, International journal of cancer.
[22] F. Marincola,et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.
[23] Yao-Tseng Chen,et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] X. Sastre,et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.
[25] F. Garrido,et al. HLA class I antigens in human tumors. , 1995, Advances in cancer research.
[26] Cécile Fizames,et al. The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.
[27] P. Stern,et al. Natural history of HLA expression during tumour development. , 1993, Immunology today.
[28] Anne E. Kwitek,et al. Dinucleotide repeat polymorphisms at the D11S419 and CD3D loci , 1990, Nucleic Acids Res..
[29] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[30] J. Strominger,et al. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131 , 1985, The Journal of experimental medicine.
[31] C. Milstein,et al. Stimulation of HLA‐A,B,C by IFN‐alpha. The derivation of Molt 4 variants and the differential expression of HLA‐A,B,C subsets. , 1985, The EMBO journal.
[32] C. Barnstable,et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.